^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABL103

    i
    Other names: ABL103, ABL 103, TRIA002, ABL-103, TRIA-002, TRIA 002
    Associations

    News

    Trials
    Company:
    ABL Bio, Handok
    Drug class:
    CD137 agonist, B7-H4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=96, Recruiting, ABL Bio, Inc.
    New P1 trial • Metastases
    |
    ABL103
    almost3years
    ABL103, A novel T-cell engaging bispecific antibody, exhibits potent in vitro and vivo antitumor activity and low toxicity via B7-H4 dependent 4-1BB activation in tumor microenvironment (AACR 2022)
    Overall, ABL103 has a strong in vitro and vivo anti-tumor activity and good safety profile via B7-H4-dependent 4-1BB activation. This strongly suggests ABL103 is a promising therapeutic agent potentially benefitting patients with B7-H4 overexpression.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • CD4 (CD4 Molecule)
    |
    CD8 expression • VTCN1 underexpression
    |
    ABL103